1. Home
  2. AES vs PRAX Comparison

AES vs PRAX Comparison

Compare AES & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo The AES Corporation

AES

The AES Corporation

HOLD

Current Price

$14.49

Market Cap

9.9B

Sector

Utilities

ML Signal

HOLD

Logo Praxis Precision Medicines Inc.

PRAX

Praxis Precision Medicines Inc.

HOLD

Current Price

$342.77

Market Cap

9.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AES
PRAX
Founded
1981
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Electric Utilities: Central
Biotechnology: Pharmaceutical Preparations
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
9.9B
9.6B
IPO Year
1996
2020

Fundamental Metrics

Financial Performance
Metric
AES
PRAX
Price
$14.49
$342.77
Analyst Decision
Hold
Strong Buy
Analyst Count
10
15
Target Price
$15.29
$572.13
AVG Volume (30 Days)
9.5M
381.1K
Earning Date
05-01-2026
05-08-2026
Dividend Yield
4.86%
N/A
EPS Growth
N/A
N/A
EPS
1.26
N/A
Revenue
$12,233,000,000.00
N/A
Revenue This Year
$5.22
N/A
Revenue Next Year
$4.81
$6,395.88
P/E Ratio
$11.49
N/A
Revenue Growth
N/A
N/A
52 Week Low
$9.46
$34.89
52 Week High
$17.65
$354.87

Technical Indicators

Market Signals
Indicator
AES
PRAX
Relative Strength Index (RSI) 51.68 59.58
Support Level $14.01 $282.49
Resistance Level $14.60 $354.87
Average True Range (ATR) 0.09 19.10
MACD 0.06 3.67
Stochastic Oscillator 88.42 86.31

Price Performance

Historical Comparison
AES
PRAX

About AES The AES Corporation

AES is a global power company that operates in 15 countries. Its generation portfolio totals over 32 gigawatts, including renewable energy (50%), gas (32%), coal (16%), and oil (2%). AES has majority ownership and operates six electric utilities distributing power to more than 2.5 million customers.

About PRAX Praxis Precision Medicines Inc.

Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.

Share on Social Networks: